Kristen Hege, MD
Dr. Kristen Hege joined Celgene in September 2010 as the San Francisco Site Head and Vice President, Translational Development, Hematology & Oncology. She has oversight of the translational development operations group and phase 1 cancer clinical programs focused on next generation kinase inhibitors, IMiDs, epigenetic therapies and immunotherapy. She participates in the management of Celgene alliances with companies focused on cancer immunotherapies and other early phase cancer programs. Prior to joining Celgene, Dr. Hege worked in a consulting capacity as Acting Chief Medical Officer for several West Coast biotechnology start ups including Aragon, Theraclone, Cellerant and the Cancer Vaccine Company, focused on small molecule, antibody and cell-based therapies for cancer and infectious diseases. In addition, Dr. Hege spent 14 years at Cell Genesys, ultimately as Vice President, Clinical Research and Development and a member of the executive team. At Cell Genesys she was responsible for early and late-stage clinical development, clinical operations, biometrics and drug safety. Programs focused on cancer immune and gene therapies, including engineered CAR T cells, cancer vaccines, and oncolytic viruses.
In addition to her biotechnology experience, Dr. Hege holds an active faculty appointment at the University of California, San Francisco (UCSF) where she is an Associate Clinical Professor of Medicine, Division of Hematology/Oncology. She served as attending physician on the inpatient leukemia/BMT service for 12 years and continues to see outpatients with benign and malignant hematologic disorders weekly.
Dr. Hege holds active board certification in Hematology and Medical Oncology. She received her MD from UCSF, Internal Medicine training at the Harvard-affiliated Brigham & Women’s Hospital, and Hematology & Oncology fellowship training at UCSF. Academic honors include graduation from Dartmouth College summa cum laude and election to the Phi Beta Kappa and Alpha Omega Alpha Academic and Medical Honor Societies. She is an active member of the American Society of Hematology, American Society of Clinical Oncology, American Association of Cancer Research and Society for the Immunotherapy of Cancer. She is an Associate Editor of the Journal of Immunotherapy of Cancer, an active member of the PhRMA Translational Development Advisory Committee, BayBio Board of Directors, Flexus Biotechnology Board of Directors (Observer), Immune Design Clinical Advisory Board and immediate Past Chairperson of the Executive Leadership Committee for the Leukemia and Lymphoma Society San Francisco Light the Night event.